Hong Wang

University of Pittsburgh - Medical Center (UPMC)

SCHOLARLY PAPERS

3

DOWNLOADS

88

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab as First Line Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer Patients with Eastern Cooperative Oncology Group Performance Status of 2

Number of pages: 24 Posted: 07 Aug 2023
University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), University of Texas at Dallas - Southwestern Medical Center, University of Texas at Dallas - Southwestern Medical Center and University of Pittsburgh - Medical Center (UPMC)
Downloads 54 (806,400)

Abstract:

Loading...

Durvalumab, non-small cell lung cancer, safety, overall survival, performance status 2

2.

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Number of pages: 95 Posted: 01 Jul 2024
University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Government of the United States of America - National Cancer Institute, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Johns Hopkins University, University of Pittsburgh Medical Center, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, University of Pittsburgh - Medical Center (UPMC), Government of the United States of America - National Cancer Institute, University of Pittsburgh, Government of the United States of America - National Cancer Institute, University of Pittsburgh, University of Pittsburgh, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, University of Pittsburgh, University of Pittsburgh Medical Center, University of Pittsburgh - Hillman Cancer Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Nanostring Technologies, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Regeneron Pharmaceuticals Inc, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, University of Pittsburgh Medical Center, University of Pittsburgh - School of Medicine, University of Pittsburgh Medical Center, Johns Hopkins University, University of Pittsburgh, Government of the United States of America - National Cancer Institute, University of Pittsburgh Medical Center and Independent
Downloads 18 (1,169,815)

Abstract:

Loading...

melanoma, resectable, neoadjuvant, TLR, innate, PD-1, PD1, CTLA-4, CTLA4

3.

Brief Report: Phase Ii Clinical Trial of Atezolizumab in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Pd-1-Directed Therapy

Number of pages: 15 Posted: 01 Oct 2024
affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pittsburgh - Medical Center (UPMC), affiliation not provided to SSRN and University of Pittsburgh - Medical Center (UPMC)
Downloads 16 (1,194,684)

Abstract:

Loading...

NSCLC, Immunotherapy, atezolizumab, immunotherapy sequencing